Project Grant HT94252310409

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...

This $1,323,505 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to explore immune-tumor cell metabolic interactions in prostate cancer among African American men. The grant recipient, Trustees of Indiana University, will leverage its expertise in biomedical sciences and public health to conduct this innovative research initiative. The award has a performance period from August 1, 2024 to July 31, 2027....

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $433,157 to the Northshore University Healthsystem Research Institute to investigate the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The primary objectives are to define the mechanisms regulating the immuno-metabolic axis in adipose tissue macrophages and tumor-associated macrophages, and determine whether a metabolically-activated macrophage...

The Defense Health Agency awarded a $468,672 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Georgia College & State University. The grant, titled "The Inclusive Cancer Care Research Equity (ICCARE) for Black Men Consortium," will fund research focused on examining health-seeking behaviors, decision-making, psychosocial effects, and coping mechanisms among Black men with prostate cancer. The project will also test the efficacy of...

The National Institute on Minority Health and Health Disparities (NIMHD) awarded $467,489 to the University of New Mexico Health Sciences Center on July 29, 2025, under the Minority Health and Health Disparities Research program (CFDA 93.307). This Project Grant, extending through June 30, 2030, supports Dr. Ryan Huebinger's research into interhospital disparities in out-of-hospital cardiac arrest (OHCA) care and outcomes. The project addresses a critical public health issue, as OHCA affects...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $658,423 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031, to conduct fundamental research on therapeutic targeting of PI3K gamma-positive tumor-associated macrophages (TAMs) in metastatic castration-resistant prostate cancer (MCRPC). The research aims to develop innovative therapeutics that reduce health disparities...

Grant Award Summary Mayo Clinic received a $558,016 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded May 8, 2026, with completion targeted for April 30, 2031. The research project investigates accelerated biological aging and immunosenescence as drivers of racial disparities in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). The study addresses the observation that African American...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Illinois at Chicago a $422,649 Project Grant under the Cancer Biology Research program (CFDA 93.396) to investigate disparities in acute myeloid leukemia (AML) treatment outcomes between racial groups. The award, effective June 1, 2026 through May 31, 2028, funds research examining why Black AML patients with mutant nucleophosmin (NPM1MUT) and wild-type FMS-like receptor tyrosine kinase (FLT3-WT)...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...